Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors
A brand from Opella will be part of the official NASA astronaut formulary
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Highlights Mirvetuximab-based regimen promise
The centre offers a full spectrum of FDA-approved services, including physiotherapy, occupational therapy, speech and language therapy, and aqua therapy
The conference focuses on the latest advances in cancer diagnosis, treatment, and patient-centric care
The campaign builds on the three-year partnership unveiled earlier this season
The license is valid for five years, effective from April 9, 2026
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
MoU aims to strengthen academia-industry collaboration in healthcare research and innovation
Subscribe To Our Newsletter & Stay Updated